Fig. 3From: Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapiesAverage predicted BCVA scores for FAc 0.2 μg/day implant and usual care in the pseudophakic and phakic populationsBack to article page